In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma

Haematologica June 2018 : haematol.2018.189241; doi:10.3324/haematol.2018.189241

http://www.haematologica.org/content/early/2018/06/04/haematol.2018.189241

Overall, our results show that the QTX125 compound obtained is a new HDAC6-specific inhibitor that causes cell-growth inhibition and programmed cell death in association with increased levels of acetylated α-tubulin, its most recognizable target. The antitumoral effect is particularly evident in MCL models, both in culture and in vivo, surpassing the efficacy of currently available HDAC6 inhibitors. Thus, QTX125 constitutes a novel candidate agent whose utility in epigenetic lymphoma therapy warrants further assessment, its efficacy in the preclinical setting having been demonstrated herein.